Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Sustained correction of associative learning deficits after brief, early treatment in a rat model of Fragile X Syndrome.

Asiminas A, Jackson AD, Louros SR, Till SM, Spano T, Dando O, Bear MF, Chattarji S, Hardingham GE, Osterweil EK, Wyllie DJA, Wood ER, Kind PC.

Sci Transl Med. 2019 May 29;11(494). pii: eaao0498. doi: 10.1126/scitranslmed.aao0498.

PMID:
31142675
2.

In memoriam: John Lisman - commentaries on CaMKII as a memory molecule.

Bear MF, Cooke SF, Giese KP, Kaang BK, Kennedy MB, Kim JI, Morris RGM, Park P.

Mol Brain. 2018 Dec 28;11(1):76. doi: 10.1186/s13041-018-0419-y.

3.

The mouse as a model for neuropsychiatric drug development.

Howe JR 6th, Bear MF, Golshani P, Klann E, Lipton SA, Mucke L, Sahin M, Silva AJ.

Curr Biol. 2018 Sep 10;28(17):R909-R914. doi: 10.1016/j.cub.2018.07.046.

PMID:
30205056
4.

Interneuron Simplification and Loss of Structural Plasticity As Markers of Aging-Related Functional Decline.

Eavri R, Shepherd J, Welsh CA, Flanders GH, Bear MF, Nedivi E.

J Neurosci. 2018 Sep 26;38(39):8421-8432. doi: 10.1523/JNEUROSCI.0808-18.2018. Epub 2018 Aug 14.

5.

Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.

Berry-Kravis EM, Lindemann L, Jønch AE, Apostol G, Bear MF, Carpenter RL, Crawley JN, Curie A, Des Portes V, Hossain F, Gasparini F, Gomez-Mancilla B, Hessl D, Loth E, Scharf SH, Wang PP, Von Raison F, Hagerman R, Spooren W, Jacquemont S.

Nat Rev Drug Discov. 2018 Apr;17(4):280-299. doi: 10.1038/nrd.2017.221. Epub 2017 Dec 8. Review.

PMID:
29217836
6.

Recovery from the anatomical effects of long-term monocular deprivation in cat lateral geniculate nucleus.

Duffy KR, Fong MF, Mitchell DE, Bear MF.

J Comp Neurol. 2018 Feb 1;526(2):310-323. doi: 10.1002/cne.24336. Epub 2017 Oct 27.

PMID:
29023717
7.

R-Baclofen Reverses Cognitive Deficits and Improves Social Interactions in Two Lines of 16p11.2 Deletion Mice.

Stoppel LJ, Kazdoba TM, Schaffler MD, Preza AR, Heynen A, Crawley JN, Bear MF.

Neuropsychopharmacology. 2018 Feb;43(3):513-524. doi: 10.1038/npp.2017.236. Epub 2017 Oct 6.

8.

Experience-Dependent Synaptic Plasticity in V1 Occurs without Microglial CX3CR1.

Schecter RW, Maher EE, Welsh CA, Stevens B, Erisir A, Bear MF.

J Neurosci. 2017 Nov 1;37(44):10541-10553. doi: 10.1523/JNEUROSCI.2679-16.2017. Epub 2017 Sep 26.

9.

Arc restores juvenile plasticity in adult mouse visual cortex.

Jenks KR, Kim T, Pastuzyn ED, Okuno H, Taibi AV, Bito H, Bear MF, Shepherd JD.

Proc Natl Acad Sci U S A. 2017 Aug 22;114(34):9182-9187. doi: 10.1073/pnas.1700866114. Epub 2017 Aug 8.

10.

Arbaclofen in fragile X syndrome: results of phase 3 trials.

Berry-Kravis E, Hagerman R, Visootsak J, Budimirovic D, Kaufmann WE, Cherubini M, Zarevics P, Walton-Bowen K, Wang P, Bear MF, Carpenter RL.

J Neurodev Disord. 2017 Jun 12;9:3. doi: 10.1186/s11689-016-9181-6. eCollection 2017.

11.

β-Arrestin2 Couples Metabotropic Glutamate Receptor 5 to Neuronal Protein Synthesis and Is a Potential Target to Treat Fragile X.

Stoppel LJ, Auerbach BD, Senter RK, Preza AR, Lefkowitz RJ, Bear MF.

Cell Rep. 2017 Mar 21;18(12):2807-2814. doi: 10.1016/j.celrep.2017.02.075.

12.

Negative Allosteric Modulation of mGluR5 Partially Corrects Pathophysiology in a Mouse Model of Rett Syndrome.

Tao J, Wu H, Coronado AA, de Laittre E, Osterweil EK, Zhang Y, Bear MF.

J Neurosci. 2016 Nov 23;36(47):11946-11958.

13.

Rapid recovery from the effects of early monocular deprivation is enabled by temporary inactivation of the retinas.

Fong MF, Mitchell DE, Duffy KR, Bear MF.

Proc Natl Acad Sci U S A. 2016 Dec 6;113(49):14139-14144. Epub 2016 Nov 17.

14.

Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial.

Veenstra-VanderWeele J, Cook EH, King BH, Zarevics P, Cherubini M, Walton-Bowen K, Bear MF, Wang PP, Carpenter RL.

Neuropsychopharmacology. 2017 Jun;42(7):1390-1398. doi: 10.1038/npp.2016.237. Epub 2016 Oct 17.

15.

Contrasting roles for parvalbumin-expressing inhibitory neurons in two forms of adult visual cortical plasticity.

Kaplan ES, Cooke SF, Komorowski RW, Chubykin AA, Thomazeau A, Khibnik LA, Gavornik JP, Bear MF.

Elife. 2016 Mar 4;5. pii: e11450. doi: 10.7554/eLife.11450.

16.

Gene expression analysis in Fmr1KO mice identifies an immunological signature in brain tissue and mGluR5-related signaling in primary neuronal cultures.

Prilutsky D, Kho AT, Palmer NP, Bhakar AL, Smedemark-Margulies N, Kong SW, Margulies DM, Bear MF, Kohane IS.

Mol Autism. 2015 Dec 21;6:66. doi: 10.1186/s13229-015-0061-9. eCollection 2015.

17.

Convergence of Hippocampal Pathophysiology in Syngap+/- and Fmr1-/y Mice.

Barnes SA, Wijetunge LS, Jackson AD, Katsanevaki D, Osterweil EK, Komiyama NH, Grant SG, Bear MF, Nägerl UV, Kind PC, Wyllie DJ.

J Neurosci. 2015 Nov 11;35(45):15073-81. doi: 10.1523/JNEUROSCI.1087-15.2015.

18.

Metabotropic glutamate receptor signaling is required for NMDA receptor-dependent ocular dominance plasticity and LTD in visual cortex.

Sidorov MS, Kaplan ES, Osterweil EK, Lindemann L, Bear MF.

Proc Natl Acad Sci U S A. 2015 Oct 13;112(41):12852-7. doi: 10.1073/pnas.1512878112. Epub 2015 Sep 28.

19.

Conserved hippocampal cellular pathophysiology but distinct behavioural deficits in a new rat model of FXS.

Till SM, Asiminas A, Jackson AD, Katsanevaki D, Barnes SA, Osterweil EK, Bear MF, Chattarji S, Wood ER, Wyllie DJ, Kind PC.

Hum Mol Genet. 2015 Nov 1;24(21):5977-84. doi: 10.1093/hmg/ddv299. Epub 2015 Aug 4.

20.

Visual recognition memory: a view from V1.

Cooke SF, Bear MF.

Curr Opin Neurobiol. 2015 Dec;35:57-65. doi: 10.1016/j.conb.2015.06.008. Epub 2015 Jul 4. Review.

21.

Erratum: Visual recognition memory, manifested as long-term habituation, requires synaptic plasticity in V1.

Cooke SF, Komorowski RW, Kaplan ES, Gavornik JP, Bear MF.

Nat Neurosci. 2015 Jun;18(6):926. doi: 10.1038/nn0615-926d. No abstract available.

PMID:
26007217
22.

Visual recognition memory, manifested as long-term habituation, requires synaptic plasticity in V1.

Cooke SF, Komorowski RW, Kaplan ES, Gavornik JP, Bear MF.

Nat Neurosci. 2015 Feb;18(2):262-71. doi: 10.1038/nn.3920. Epub 2015 Jan 19. Erratum in: Nat Neurosci. 2015 Jun;18(6):926.

23.

Contribution of mGluR5 to pathophysiology in a mouse model of human chromosome 16p11.2 microdeletion.

Tian D, Stoppel LJ, Heynen AJ, Lindemann L, Jaeschke G, Mills AA, Bear MF.

Nat Neurosci. 2015 Feb;18(2):182-4. doi: 10.1038/nn.3911. Epub 2015 Jan 12.

24.

Microchip amplifier for in vitro, in vivo, and automated whole cell patch-clamp recording.

Harrison RR, Kolb I, Kodandaramaiah SB, Chubykin AA, Yang A, Bear MF, Boyden ES, Forest CR.

J Neurophysiol. 2015 Feb 15;113(4):1275-82. doi: 10.1152/jn.00629.2014. Epub 2014 Nov 26.

25.

Higher brain functions served by the lowly rodent primary visual cortex.

Gavornik JP, Bear MF.

Learn Mem. 2014 Sep 15;21(10):527-33. doi: 10.1101/lm.034355.114. Print 2014 Oct. Review.

26.

Extinction of an instrumental response: a cognitive behavioral assay in Fmr1 knockout mice.

Sidorov MS, Krueger DD, Taylor M, Gisin E, Osterweil EK, Bear MF.

Genes Brain Behav. 2014 Jun;13(5):451-8. doi: 10.1111/gbb.12137. Epub 2014 Apr 30.

27.

Learned spatiotemporal sequence recognition and prediction in primary visual cortex.

Gavornik JP, Bear MF.

Nat Neurosci. 2014 May;17(5):732-7. doi: 10.1038/nn.3683. Epub 2014 Mar 23.

28.

Divergent dysregulation of gene expression in murine models of fragile X syndrome and tuberous sclerosis.

Kong SW, Sahin M, Collins CD, Wertz MH, Campbell MG, Leech JD, Krueger D, Bear MF, Kunkel LM, Kohane IS.

Mol Autism. 2014 Feb 24;5(1):16. doi: 10.1186/2040-2392-5-16.

29.

How the mechanisms of long-term synaptic potentiation and depression serve experience-dependent plasticity in primary visual cortex.

Cooke SF, Bear MF.

Philos Trans R Soc Lond B Biol Sci. 2013 Dec 2;369(1633):20130284. doi: 10.1098/rstb.2013.0284. Print 2014 Jan 5. Review. Erratum in: Philos Trans R Soc Lond B Biol Sci. 2014 Apr 5;369(1639):20140021.

30.

STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study.

Erickson CA, Veenstra-Vanderweele JM, Melmed RD, McCracken JT, Ginsberg LD, Sikich L, Scahill L, Cherubini M, Zarevics P, Walton-Bowen K, Carpenter RL, Bear MF, Wang PP, King BH.

J Autism Dev Disord. 2014 Apr;44(4):958-64. doi: 10.1007/s10803-013-1963-z.

PMID:
24272415
31.

Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome?

Lohith TG, Osterweil EK, Fujita M, Jenko KJ, Bear MF, Innis RB.

Mol Autism. 2013 May 24;4(1):15. doi: 10.1186/2040-2392-4-15.

32.

Fragile X mental retardation protein and synaptic plasticity.

Sidorov MS, Auerbach BD, Bear MF.

Mol Brain. 2013 Apr 8;6:15. doi: 10.1186/1756-6606-6-15. Review.

33.

A cholinergic mechanism for reward timing within primary visual cortex.

Chubykin AA, Roach EB, Bear MF, Shuler MG.

Neuron. 2013 Feb 20;77(4):723-35. doi: 10.1016/j.neuron.2012.12.039.

34.

Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome.

Osterweil EK, Chuang SC, Chubykin AA, Sidorov M, Bianchi R, Wong RK, Bear MF.

Neuron. 2013 Jan 23;77(2):243-50. doi: 10.1016/j.neuron.2012.01.034.

35.

Lifting the mood on treating fragile X.

Osterweil EK, Kind PC, Bear MF.

Biol Psychiatry. 2012 Dec 1;72(11):895-7. doi: 10.1016/j.biopsych.2012.09.017. No abstract available.

PMID:
23121869
36.

The BCM theory of synapse modification at 30: interaction of theory with experiment.

Cooper LN, Bear MF.

Nat Rev Neurosci. 2012 Nov;13(11):798-810. doi: 10.1038/nrn3353. Review.

PMID:
23080416
37.

Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen.

Henderson C, Wijetunge L, Kinoshita MN, Shumway M, Hammond RS, Postma FR, Brynczka C, Rush R, Thomas A, Paylor R, Warren ST, Vanderklish PW, Kind PC, Carpenter RL, Bear MF, Healy AM.

Sci Transl Med. 2012 Sep 19;4(152):152ra128.

38.

Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial.

Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, Mu Y, Nguyen DV, Gonzalez-Heydrich J, Wang PP, Carpenter RL, Bear MF, Hagerman RJ.

Sci Transl Med. 2012 Sep 19;4(152):152ra127.

39.

Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.

Michalon A, Sidorov M, Ballard TM, Ozmen L, Spooren W, Wettstein JG, Jaeschke G, Bear MF, Lindemann L.

Neuron. 2012 Apr 12;74(1):49-56. doi: 10.1016/j.neuron.2012.03.009.

40.

The pathophysiology of fragile X (and what it teaches us about synapses).

Bhakar AL, Dölen G, Bear MF.

Annu Rev Neurosci. 2012;35:417-43. doi: 10.1146/annurev-neuro-060909-153138. Epub 2012 Apr 5. Review.

41.

Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities.

Zoghbi HY, Bear MF.

Cold Spring Harb Perspect Biol. 2012 Mar 1;4(3). pii: a009886. doi: 10.1101/cshperspect.a009886. Review.

42.

Mutations causing syndromic autism define an axis of synaptic pathophysiology.

Auerbach BD, Osterweil EK, Bear MF.

Nature. 2011 Nov 23;480(7375):63-8. doi: 10.1038/nature10658.

43.

A biophysically-based neuromorphic model of spike rate- and timing-dependent plasticity.

Rachmuth G, Shouval HZ, Bear MF, Poon CS.

Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):E1266-74. doi: 10.1073/pnas.1106161108. Epub 2011 Nov 16.

44.

Stimulus-selective response plasticity in the visual cortex: an assay for the assessment of pathophysiology and treatment of cognitive impairment associated with psychiatric disorders.

Cooke SF, Bear MF.

Biol Psychiatry. 2012 Mar 15;71(6):487-95. doi: 10.1016/j.biopsych.2011.09.006. Epub 2011 Oct 21. Review.

PMID:
22019003
45.

Translating glutamate: from pathophysiology to treatment.

Javitt DC, Schoepp D, Kalivas PW, Volkow ND, Zarate C, Merchant K, Bear MF, Umbricht D, Hajos M, Potter WZ, Lee CM.

Sci Transl Med. 2011 Sep 28;3(102):102mr2. doi: 10.1126/scitranslmed.3002804. Review.

46.

New views of Arc, a master regulator of synaptic plasticity.

Shepherd JD, Bear MF.

Nat Neurosci. 2011 Mar;14(3):279-84. doi: 10.1038/nn.2708. Epub 2011 Jan 30. Review.

PMID:
21278731
47.

Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndrome.

Krueger DD, Osterweil EK, Chen SP, Tye LD, Bear MF.

Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2587-92. doi: 10.1073/pnas.1013855108. Epub 2011 Jan 24.

48.

Visual experience induces long-term potentiation in the primary visual cortex.

Cooke SF, Bear MF.

J Neurosci. 2010 Dec 1;30(48):16304-13. doi: 10.1523/JNEUROSCI.4333-10.2010. Erratum in: J Neurosci. 2011 Aug 17;31(33):12058.

49.

Toward fulfilling the promise of molecular medicine in fragile X syndrome.

Krueger DD, Bear MF.

Annu Rev Med. 2011;62:411-29. doi: 10.1146/annurev-med-061109-134644. Review.

50.

Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome.

Osterweil EK, Krueger DD, Reinhold K, Bear MF.

J Neurosci. 2010 Nov 17;30(46):15616-27. doi: 10.1523/JNEUROSCI.3888-10.2010.

Supplemental Content

Support Center